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REVIEW
Abstract: Asthma is characterized by inflammation and airway hyperresponsiveness, which
results in episodic airflow obstruction. It is diagnosed once a compatible clinical history plus
objective evidence of diurnal variability in peak expiratory flow or significant reversibility to
inhaled bronchodilator is documented. In accordance with current guidelines, measures of
airway calibre and symptoms allow patients and clinicians to assess the degree of asthma
control and titrate pharmacotherapy. However, these parameters fail to reflect the extent of
underlying endobronchial inflammation and airway hyperresponsiveness, which in turn
suggests that additional measures of asthma control may be of benefit. This evidence-based
review highlights ways by which inflammation and airway hyperresponsiveness can be assessed
and how they may provide additional useful information in the diagnosis and management of
asthmatic patients.
Keywords: asthma, inflammation, airway hyperresponsiveness, eosinophils, corticosteroids,
beta-agonists
Introduction
Asthma is a common condition with a prevalence of up to 20% in young adult Western
populations (ISAAC 1998). The characteristic pathological feature in asthma is
underlying inflammation of the bronchial mucosa. As a consequence of the complex
interplay between a plethora of inflammatory cells and mediators, the airways exhibit
an abnormal response to inhaled bronchoconstrictor stimuli, otherwise known as
airway hyperresponsiveness (AHR) (Currie et al 2004). This causes smooth muscle
to contract and relax periodically, with the subsequent perception of symptoms. Due
to the episodic and reversible nature of the asthmatic inflammatory process, patients
intermittently report symptoms such as cough, wheeze, breathlessness, chest tightness,
and reduced exercise tolerance.
The diagnosis of asthma is made with a combination of compatible clinical history
and objective evidence such as peak expiratory flow (PEF) variability over several
weeks of diurnal monitoring. Patients are asked to document serial recordings over a
2-week period; 20% variability in PEF is considered to be relatively specific, although
insensitive as a diagnostic threshold (British Thoracic Society; Scottish Intercollegiate
Guidelines Network 2003). A significant degree of reversibility following inhaled
bronchodilator or oral corticosteroids can also be useful, especially in patients with
impaired lung calibre. For example, a 15% plus 200 mL improvement in forced
expiratory volume in 1 second (FEV1) or 20% plus 60 L/min improvement in PEF is
considered classical. Once the diagnosis is secured, treatment is usually indicated
and varies from intermittent use of short acting β2-agonists to combinations of inhaled
and oral agents.
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A common problem with the everyday diagnosis of
asthma is that many patients – particularly those at the milder
end of the spectrum – exhibit normal lung function, implying
that significant reversibility to either inhaled bronchodilator
or oral corticosteroids cannot be demonstrated. Moreover,
due to the inherent variability of the disease process itself,
lung function can be normal when patients are not exposed
to a bronchoconstrictor stimulus. Indeed, despite normal or
near normal lung function, asthmatics often exhibit
persistent AHR (Boulet et al 1994; Vignola et al 1998). In
such cases of diagnostic uncertainty, current guidelines
suggest performing an exercise test in an attempt to
demonstrate a significant fall in PEF or FEV1 (British
Thoracic Society; Scottish Intercollegiate Guidelines
Network 2003), although these can at times be difficult to
arrange and are not suitable for all patients.
To compound these problems surrounding diagnosis,
monitoring the control of asthma and deciding when to alter
antiinflammatory therapy can frequently cause uncertainty.
For instance, traditional parameters guiding changes in
treatment, such as symptoms and reliever use are by their
nature highly subjective and may not correspond to changes
in endobronchial inflammation, AHR, or airflow obstruction.
Moreover, daily monitoring of PEF requires adequate patient
compliance, while a solitary FEV1 measurement at a primary
or secondary care clinic may not be representative of airway
calibre over the preceding weeks. It may also be artificially
elevated when patients have used a short-acting β2-agonist
several hours prior to its measurement.
Additional parameters incorporating the measurement
of biomarkers of airway inflammation (Table 1) and AHR
are useful adjuncts in both the diagnosis and subsequent
management of asthma. They can be useful in avoiding
potential pitfalls when assessing subjective measures of
asthma control and provide the clinician with an insight into
whether underlying inflammation is adequately suppressed
and AHR attenuated. This in turn permits a way in which
antiinflammatory therapy can be titrated with both potential
short- and long-term benefit to the patient. This evidence-
based review outlines some problems of conventional
measure of asthma control and the different methods of
measuring biomarkers of inflammation in asthma, and
illustrates ways in which they have been shown to help make
the diagnosis and titrate antiinflammatory treatment to
achieve better long-term asthma control.
Conventional measures of asthma
control
Measures of airway calibre are frequently recorded indices
of asthma control in day-to-day clinical practice. PEF and
FEV1 are easily measured in both primary and secondary
care settings and minimal training is required for patient
and clinician. The forced mid-expiratory flow (FEF25–75),
considered to be a more sensitive reflection of small airway
calibre, tends to be effort-dependent and less reproducible
than successive FEV1 measurements. It is important to note
that such parameters reflect airway geometry and provide
little or no insight into the extent of underlying inflammation
or AHR. Indeed, these particular end points tend to be greatly
influenced by drugs that act primarily by relaxing airway
smooth muscle, such as long-acting β2-agonists. Although
long-acting β2-agonists are potent bronchodilators, they are
devoid of in vivo antiinflammatory activity (Roberts et al
1999; Calhoun et al 2001), which could be of potential
concern in long-term asthma control, particularly in patients
with erratic adherence to antiinflammatory therapy.
The FEV1 is of limited value in measuring the effects of
moderate to high doses of inhaled corticosteroids. For
example, in a meta-analysis of 8 randomized placebo
controlled trials (n = 2324 subjects), Holt et al (2001)
demonstrated that the maximal effect upon FEV1 was
observed at daily fluticasone doses of less than 500 µg (a
beclomethasone equivalent dose of less than 1000 µg).
Indeed, at daily doses above 800 µg of beclomethasone or
equivalent, the dose-response curve for beneficial effects
becomes flat (in terms of lung function), while for systemic
adverse effects it becomes significantly steeper (Lipworth
1999). In another meta-analysis of 25 studies, the dose-
response effect of high doses of inhaled corticosteroids
(≥ 1000 µg/day) was compared with low-to-medium doses
(< 1000 µg/day) in terms of AHR to bronchoconstrictor
stimuli (Currie, Fowler, et al 2003). In this study, high doses
of inhaled corticosteroids conferred significantly superior
attenuation of AHR (a 2.2 doubling dose/concentration shift)
than lower doses (a 1.3 doubling dose/concentration shift).
This highlights the more sensitive nature of assessment of
Table 1 Different inflammatory biomarkers currently used
Inflammatory biomarker 
Sputum eosinophils
Sputum ECP 
Blood eosinophils
Blood ECP
Exhaled nitric oxide
Airway hyperresponsiveness to an indirect bronchoconstrictor stimulus
Abbreviations: ECP, eosinophilic cationic protein.Therapeutics and Clinical Risk Management 2005:1(2) 85
Airway hyperresponsiveness and inflammatory biomarkers
AHR compared with FEV1 in terms of effects of inhaled
corticosteroids.
In a study of moderate to severe asthmatics, Pauwels et
al (1997) demonstrated an additive effect on frequency of
severe exacerbations by formoterol, over and above the
beneficial effect already observed with low and medium
doses of budesonide. In other words, budesonide reduced
frequency of exacerbations by its antiinflammatory effect,
while formoterol produced a further reduction by stabilizing
airway smooth muscle (Currie, Jackson, et al 2003). In the
same study, the additive effect of formoterol to budesonide
200 µg/day on severe exacerbation rates over 1 year, was
smaller than optimizing the inhaled corticosteroid dose from
200 µg/day to 800 µg/day (a 26% versus 49% reduction in
exacerbations, respectively). Moreover, there was a
disconnection between lung function and exacerbations; in
other words, despite a significant reduction in exacerbations,
FEV1 and PEF were unchanged when comparing
budesonide 200 µg/day with budesonide 800 µg/day. This
indicates that when optimizing the dose of inhaled
corticosteroid, lung function is relatively distant from the
underlying inflammatory process and not always related to
more long-term effects.
In another study, montelukast was administered to mild-
to-moderate asthmatics receiving 500 µg/day of fluticasone
plus salmeterol (Currie, Lee, et al 2003). Despite no change
in FEV1 or PEF, the addition of montelukast did confer
significant reductions in inflammatory biomarkers including
AHR to adenosine 5-monophoshate (AMP), exhaled nitric
oxide (NO), and blood eosinophils (all p < 0.05). This
dissociation between such inflammatory biomarkers and
lung function, further demonstrates that the latter is relatively
distant from the underlying inflammatory process. As a
consequence, potential benefits of antiinflammatory therapy
may be missed when patients and clinicians titrate therapy
according to serial lung function measurements. In another
randomized placebo controlled study of mild persistent
asthmatics (mean FEV1 80% predicted), the effects of
fluticasone 1000 µg/day was compared with half the dose
in combination with salmeterol (Currie, Bates, et al 2003).
Optimizing the inhaled corticosteroid dose conferred
superiority (p < 0.05) compared with half the dose combined
with salmeterol in terms of inflammatory biomarkers but
not lung function (Figure 1). This finding again highlights
the fact that monitoring lung function alone may miss
potentially beneficial effects of antiinflammatory therapy,
further suggesting that it is a relatively downstream
consequence of the asthmatic inflammatory process. Thus,
Figure 1 Absolute geometric mean (geometric SE) for (a) AMP PC20 and (b)
exhaled NO at baseline and after treatment with daily doses of fluticasone
propionate 500 µg (FP; hatched bars) and fluticasone propionate 250 µg/salmeterol
50 µg/combination inhaler (FP + SM; double hatched bars). *Denotes significant
(p < 0.05) difference from baseline, † denotes significant (p < 0.05) difference
between randomized treatments. Source: Currie GP, Bates CE, Lee DK, et al.
2003. Effects of fluticasone plus salmeterol versus twice the dose of fluticasone
in asthmatic patients. Eur J Clin Pharmacol, 59:11–15. Reproduced with permission
from Springer. Abbreviations: AMP, adenosine 5-monophoshate; NO, exhaled
nitric oxide.
(a)
(b)
†
†Therapeutics and Clinical Risk Management 2005:1(2) 86
Currie et al
while end points such as lung function are of undoubted
value, clinicians must not lose sight of the basic patho-
physiological hallmarks of the asthma syndrome (ie, AHR
and inflammation), which may in turn be responsible for
continuing symptoms and the morbidity associated with
uncontrolled asthma.
Airway hyperresponsiveness to
bronchoconstrictor stimuli
AHR results in episodic bronchoconstriction and is one of
the hallmark features of asthma (Currie et al 2004). It is
defined as abnormal airway narrowing in response to a
provoking stimulus. AHR can be assessed pharmaco-
logically with methacholine, histamine, mannitol, and AMP
or using naturally occurring physical stimuli, for example,
hyperventilation with cold air and exercise. It can be
regarded as a consequence of inflammation, and is often
linked to the degree of underlying inflammation (Wardlaw
et al 1988; Robinson et al 1993; Gibson et al 2000).
From a practical point of view, bronchoprovocation is
carried out using doubling doses or concentrations (twofold
increments) of a given stimulus. At regular intervals (usually
several minutes depending on the protocol) the best of
several FEV1 measurements is recorded. The procedure is
usually terminated after a predetermined fall in FEV1 is
achieved (often a 20% fall). Construction of a log dose-
response curve is followed by linear interpolation, allowing
the provocative dose or concentration of stimulant causing
a 20% fall in FEV1 to be calculated (PD20 or PC20). Recent
data have shown that calculation of a PD15 or PC15 (ie, the
dose or concentration causing a 15% fall in FEV1) can
produce similar results as compared with when a PD20 or
PC20 are calculated (Fardon, Currie, et al 2004; Fardon TC,
Fardon EJ, et al 2004). This in turn reduces the length of
bronchial challenge time, minimizes the chance of a
precipitous fall in FEV1 and means that patients inhale
smaller doses or concentrations of stimulant. At the
completion of a bronchial challenge test, patients are usually
given a short acting β2-agonist to quicken their return to
pre-test FEV1 or allowed to recover spontaneously.
It is important to point out that bronchial challenge tests
do have several drawbacks: they can be difficult to organize,
require access to specialist equipment, and can be time-
consuming, although an abbreviated methacholine challenge
test can take less than 30 minutes (Cockcroft et al 2001).
In the laboratory, bronchial provocation tests are used
to assess the presence and severity of AHR and provide
information on effects of treatment. Currently however,
assessing AHR is principally carried out in clinical research
settings and very infrequently in the day-to-day diagnosis
or management of asthma. Histamine and methacholine are
commonly used direct bronchoconstrictor stimuli, which act
directly upon effector cells such as airway smooth muscle
causing contraction and narrowing of the airway. In contrast,
indirectly acting bronchoconstrictor stimuli (for example,
AMP, mannitol, and hypertonic saline) act indirectly upon
primed mast cells and neural pathways causing release of
inflammatory mediators such as histamine and leukotrienes
(Lee et al 2003). This in turn leads to smooth muscle
contraction. Assessing AHR to indirect stimuli tends to be
better correlated with the degree of underlying airway
inflammation, particularly in relation to sputum eosinophils
and exhaled NO (van Den Toorn et al 2000; Van Den Berge
et al 2001). Moreover, the improvements in AMP PC20 are
greater with antiinflammatory therapy than effects upon the
methacholine PD or PC20 (O’Connor et al 1992; Wilson and
Lipworth 2000).
Figure 2 Correlations between (a) AMP PC20 versus mannitol PD15, (b) AMP
PC15 versus mannitol PD15. Source: Currie GP, Haggart K, Brannan JD, et al. 2003.
Relationship between airway hyperresponsiveness to mannitol and adenosine
monophosphate. Allergy, 58:762–6. Reproduced with permission from Blackwell
Publishers. Abbreviations: AMP, adenosine 5-monophoshate.
(a)
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Mannitol is a potentially useful bronchoconstrictor
stimulus and can be used to assess AHR (Anderson et al
1997). When given as a dry powder, inhaled mannitol
increases the surface osmolarity of the bronchial mucosa
resulting in the release of inflammatory mediators from a
variety of cells. From a practical point of view, mannitol
bronchoprovocation does not require a nebulizer and can
be performed using a simple handheld inhaler device.
Moreover, when compared with other indirect challenges
(eg, exercise), the use of mannitol results in a more
controlled reduction of lung function. This is due to the
carefully observed sequential fall in FEV1 after each
inhalation, allowing the procedure to be stopped
immediately after the desired reduction and reduces the
chance of excessive airway narrowing. Furthermore, the
degree of AHR to inhaled mannitol correlates closely to the
airway response following inhaled AMP (Figure 2) (Currie,
Haggart, et al 2003).
Inflammatory biomarkers in
asthma
Eosinophils
Eosinophilic inflammation is well recognized to be a major
feature in the pathogenesis of asthma. Following
eosinophilopoiesis in bone marrow, regulated by interleukin
(IL)-3, IL-5, and GM-CSF (Warlaw 1999), eosinophils
migrate from the circulation to pulmonary airways in
response to various cytokines. Peripheral blood eosinophils
are increased in asthma and fall after introduction of inhaled
corticosteroids (Evans et al 1993; Currie, Syme-Grant, et al
2003); however, it is pertinent to be aware that they are also
raised in other conditions.
With more invasive assessment, it has been demonstrated
that eosinophil levels in induced sputum can provide more
direct and useful information in the evaluation of asthma
(Parameswaran and Hargreave 2001). Patients are pre-
treated with inhaled salbutamol and then undergo three
sequential inhalations of 3%, 4%, and 5% hypertonic saline
with 5–10 minutes of each concentration (Parameswaran
and Hargreave 2001). Salivary contamination is minimized
by asking the subject to blow their nose and rinse their mouth
prior to expectorating at 5–10-minute intervals. Inconsistent
results in terms of a step-wise relationship between inhaled
corticosteroid dose versus reduction in sputum eosinophils
have been produced (Jatakanon et al 1999; Taylor et al 1999).
For example, dose-related changes were observed in sputum
eosinophils with fourfold increments in inhaled budesonide
doses (Jatakanon et al 1999), although in contrast Taylor et
al (1999) failed to demonstrate such a dose-response
relationship. In the latter study however, a dose-response
relationship for AHR to AMP was observed following
treatment with 100, 400, and 1600 µg/day of ciclesonide.
Eosinophilic cationic protein (ECP) is one of several
granular proteins released from eosinophils, and is a
reflection of activated circulating eosinophils. However, the
use of serum ECP as a non-invasive guide in asthma
management has produced inconsistent and generally
disappointing results (Wever et al 1994; Ferguson et al 1995;
Meijer et al 2002). For example, in a study of 20 asthmatics
who had been corticosteroid free for 4 weeks, the addition
of 200 µg/day of inhaled fluticasone for 2 weeks failed to
significantly reduce serum ECP levels (Currie, Syme-Grant,
et al 2003). In the same study, a small though significant
reduction (1.3-fold) in blood eosinophils was observed
(Figure 3). It is important to note that more impressive
changes in sputum eosinophils (4.3-fold), exhaled NO
(1.8-fold), AHR to methacholine (2.3-fold), and sputum ECP
(2.2-fold) were observed (Figure 3). This in turn implies
that systemic indices of asthma control such as serum ECP
and blood eosinophils are relatively distant from the
asthmatic inflammatory process occurring in the airways.
As a consequence, they are unable to provide a sufficiently
strong signal from which the effects of inhaled cortico-
steroids or other antiinflammatory therapy can be observed.
Exhaled nitric oxide
NO is produced from respiratory epithelium and
inflammatory cells by several NO synthase isoforms.
Inflammatory cells are probably the major source of NO
over and above airway epithelium and in patients with
asthmatic airway inflammation, the expression of NO
synthases is increased. As a consequence, elevated levels of
exhaled NO are often detected in asthmatic individuals
compared with matched controls (Kharitonov et al 1994).
Previous data have demonstrated that the level of exhaled
NO is significantly correlated with eosinophils in both
bronchoalveolar lavage and induced sputum (Jatakanon et
al 1998; Warke et al 2002). In a cross-sectional study by
Sippel et al (2000), exhaled NO was not significantly
correlated to FEV1, again demonstrating that measures of
airway calibre are disconnected from the asthmatic
inflammatory process.
Exhaled NO is reduced by both steroidal and non-
steroidal antiinflammatory treatments such as leukotriene
receptor antagonists (Bisgaard et al 1999; Bratton et al 1999;
Currie, Lee, et al 2003). However, the dose-response curveTherapeutics and Clinical Risk Management 2005:1(2) 88
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for effects of inhaled corticosteroids upon exhaled NO
becomes flat at daily doses greater than 800 µg of budesonide
(Wilson and Lipworth 2000). As a consequence, this finding
may well limit its sensitivity as a marker for disease severity
and a measure of disease progression in patients using higher
doses of inhaled corticosteroids.
Diagnosis of asthma
Airway hyperresponsiveness
Assessing AHR to methacholine is a recognized tool in the
diagnosis in asthma (Crapo et al 2000). Indeed, in patients
with symptoms but normal airway responsiveness, asthma
is unlikely to be the diagnosis. Although AHR is one of the
hallmark features of asthma, it can be demonstrated in other
disease processes, such as chronic obstructive pulmonary
disease, congestive cardiac failure, cystic fibrosis, allergic
rhinitis (all without the presence of asthma) (Ramsdell et al
1982; Yan et al 1985; Du Toit et al 1986). Methacholine
challenge is most useful in patients whose pre-test
probability score for asthma is 30%–70%, or in other words
when diagnostic uncertainty exists (Perpina et al 1993). In
such situations, clinicians are unable to predict the extent
of AHR to methacholine (Dales et al 1988), in turn
suggesting that there are few clinical clues to allow accurate
Figure 3 Bargraphs illustrate absolute values after salmeterol 100 µg/day (SM) washout (empty bars) and after 2 weeks of fluticasone 200 µg/salmeterol 100 µg/day
(FP/SM) treatment (hatched bars) for (a) sputum eosinophils, (b) exhaled NO, (c) methacholine PD20, and (d) serum ECP. *Denotes significant (p < 0.05) difference
from salmeterol washout. Source: Currie GP, Syme-Grant NJ, McFarlane LC, et al. 2003. Effects of low dose fluticasone/salmeterol combination on surrogate
inflammatory markers in moderate persistent asthma. Allergy, 58:602–7. Reproduced with permission from Blackwell Publishers. Abbreviations: ECP, eosinophilic
cationic protein; NO, exhaled nitric oxide.
(a) (b)
(c) (d)Therapeutics and Clinical Risk Management 2005:1(2) 89
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assessment of AHR. When compared with PEF variability
and bronchodilator reversibility, assessing the degree of
AHR to methacholine has proved to be a more useful aid in
the diagnosis of asthma (Goldstein et al 2001; Hunter et al
2002). Whether measuring AHR to indirect broncho-
constrictor stimuli provides further benefit and certainty in
diagnosis requires prospective evaluation.
Several contraindications exist to performing bronchial
challenge tests such as moderately severe airflow
obstruction, pregnancy and lactation, uncontrolled
hypertension, and inability to correctly perform spirometry
(Crapo et al 2000). The American Thoracic Society has also
suggested stratifying the degree of AHR to methacholine
according to the PC20 value. For example, normal AHR is
considered present when the PC20 is > 16 mg/mL, while
borderline, mild, and moderate-to-severe AHR is present
when respective values are 4.0–1.6 mg/mL, 1.0–4.0 mg/mL,
and < 1 mg/mL (Crapo et al 2000).
Exhaled nitric oxide
In the laboratory setting, the measurement of exhaled NO
is quick and easy. For instance, patients are asked to exhale
through a mouthpiece for between 5 and 20 seconds to
eliminate dead space and nasal contamination, and the end
tidal NO can be obtained as the plateau value at the end of
exhalation (Kharitonov et al 1996). From a diagnostic point
of view, NO has been shown to effectively discriminate
between asthmatic and non-asthmatic subjects (Alving et
al 1993; Kharitonov et al 1994). In another study, Taylor et
al (1999) evaluated 47 consecutive patients with symptoms
suggestive of asthma, and sensitivities and specificities were
obtained for PEF, spirometry, and inflammatory biomarkers,
in addition to changes in these parameters after a
corticosteroid trial. Sensitivities for each of the conventional
tests (0%–47%) were significantly lower than for exhaled
NO (88%) and sputum eosinophils (86%), while results for
conventional tests of airway calibre were not improved
following a corticosteroid trial. Thus, exhaled NO and
measurement of induced sputum eosinophils were superior
to conventional approaches, with the implication that
incorporating NO levels into the initial assessment of
patients with possible asthma can be a useful adjunct.
Titrating asthma therapy
Measuring AHR has been shown to be a useful guide in the
management of asthma. In a parallel group study involving
75 adults, Sont et al (1999) titrated the dose of inhaled
corticosteroid according to conventional measures of airway
calibre in conjunction with AHR to methacholine. Patients
in whom additional AHR was assessed had fewer
exacerbations and symptoms, superior spirometry, and a
reduction in thickness of subepithelial reticular layer at
bronchoscopic lung biopsy. Despite their observations, the
exact association between inflammation and AHR remains
unclear and, at times, contentious. It is without doubt that
assessment of AHR is a useful non-invasive tool and
provides complementary information to that of more
conventional outcome measures. Compared with the use of
direct agents, assessing AHR to indirect bronchoconstrictor
stimuli is superior in the detection of the changes associated
with inflammation (O’Connor et al 1992; Wilson and
Lipworth 2000). Indeed, perhaps in the study by Sont et al
(1999), even better long-term control of asthma might have
been achieved if they had evaluated AHR using agents such
as AMP or mannitol.
Green et al (2002), evaluated whether an asthma
management strategy targeted against sputum eosinophils
could lead to better asthma control than using standard
guidelines alone. In this prospective study, 74 patients with
moderate-to-severe asthma were randomized to have
treatment altered on the basis of symptoms plus sputum
eosinophil count or according to conventional measures
alone. It was discovered that the sputum eosinophil count
was 63% lower over 12 months in the eosinophil
management group than in the conventional management
group (p = 0.002). Moreover, those in the sputum
management group had fivefold fewer severe asthma
exacerbations than patients treated according to standard
guidelines (35 versus 109, p = 0.01).
Despite transforming the management of asthma, inhaled
corticosteroids exhibit adverse effects in a dose-dependent
fashion. Current guidelines suggest back titration of asthma
therapy once symptoms and lung function have been stable
over a preceding 3–6-month period (British Thoracic
Society; Scottish Intercollegiate Guidelines Network 2003).
Leuppi et al (2001) evaluated putative markers, which could
be helpful in guiding clinicians in the step wise reduction
of inhaled corticosteroid doses. They evaluated 50 patients
with well controlled asthma (median daily inhaled
corticosteroid dose of 1000 µg). The inhaled corticosteroid
dose was halved every 2 months; AHR to mannitol and
histamine, spirometry, exhaled NO, and sputum eosinophils
were measured at baseline and at monthly intervals. Thirty-
nine subjects experienced an asthma exacerbation, while
seven subjects were successfully weaned off inhaledTherapeutics and Clinical Risk Management 2005:1(2) 90
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corticosteroids. The most important predictors of failure of
inhaled corticosteroid reduction were the demonstration of
AHR to both histamine and mannitol at baseline (p = 0.039),
and AHR to mannitol during the dose reduction phase of
the study (p = 0.02). In the same study, AHR to mannitol
was more pronounced and there were more sputum
eosinophils present before a failed reduction of inhaled
corticosteroid dose. In contrast, there were no significant
differences in symptoms, spirometry, or NO between periods
where failed reduction of doses occurred. These findings
suggest that knowledge of the extent of AHR to mannitol or
extent of sputum eosinophilia may be useful in back titration
of inhaled corticosteroids.
In another study of 78 patients with mild-moderate
asthma, the ability of exhaled NO in predicting loss of
control in asthma following steroid withdrawal was
evaluated (Jones et al 2001). Comparisons were made
against sputum eosinophils and AHR to hypertonic saline.
Patients had their inhaled corticosteroids withdrawn until
their asthma became uncontrolled (60 patients) or for a
maximum of 6 weeks. Significant correlations between the
changes in exhaled NO and symptoms (p < 0.0001), FEV1
(p < 0.002), sputum eosinophils (p < 0.0002), and saline PD15
(p < 0.0002) were observed. Isolated measurements and also
changes in exhaled NO levels had positive predictive values
of over 80% for predicting loss of asthma control. Perhaps
not surprisingly, results were similar to those obtained by
measuring sputum eosinophils and AHR to saline. Thus,
knowledge of sputum eosinophilia together with exhaled
NO levels and AHR can be useful in allowing asthma therapy
to be successfully back titrated.
Conclusion
It can be seen therefore that better asthma control can be
achieved when an inflammatory biomarker is included in
the algorithm by which asthma therapy is tailored. Indeed,
concomitant assessment of AHR and other inflammatory
biomarkers are undoubtedly of value in diagnosis, reducing
exacerbation frequency and prevention of airway
remodeling. However, it does have to be borne in mind that
asthma guidelines and clinical tools by which treatment is
titrated require to be practical, evidence-based, and usable
in everyday real life. Not only could this be important in
terms of appropriate dosing regimes, but also important in
back titrating therapy. Unfortunately, there is no widely
accepted and straightforward method of identifying airway
inflammation or AHR, and the methods described above
tend to be preserved for research purposes and use in
specialized centres only.
Inhaled corticosteroids are the first line treatment in the
management of asthma. In adults, the recommended dose
is between 400–800 µg/day of beclomethasone or equivalent
(British Thoracic Society; Scottish Intercollegiate
Guidelines Network 2003). Other than clinical markers of
asthma severity such as symptoms and lung function, there
is little else to guide clinicians as to when a long-acting β2-
agonist or other second line agent such as a leukotriene
receptor antagonist should be started. In this respect, a non-
invasive inflammatory biomarker could help in the
management of patients. For example, it is highly likely
that in some patients, only low doses of inhaled
corticosteroid (400 µg/day) are sufficient to suppress airway
inflammation, and that the addition of a long-acting β2-
agonist is perfectly acceptable in patients with persistent
symptoms – especially in those with impaired lung function.
Conversely, some patients with more severe endobronchial
inflammation may well require daily doses greater than
800 µg of beclomethasone or equivalent before inflammation
is adequately suppressed. The decision to start second line
therapy can often be fairly arbitrary and knowledge of
whether inflammation is adequately suppressed would be
useful in ensuring optimum benefit and prevention of more
long-term adverse sequelae such as airway remodeling. In
the ideal world, clinicians would have access to a simple
test that would assist them in this respect; characteristics of
the “ideal” inflammatory biomarker are shown in Table 2.
The more widespread use of such a tool would also be
of value in patients already maintained on inhaled
corticosteroids plus other second line therapy. For example,
an inhaled corticosteroid combined with a long-acting β2-
agonist in a single inhaler is becoming a more popular way
in which potent antiinflammatory and bronchodilator
therapy, respectively, is delivered to the lungs. This in turn
means that fewer devices and inhalations are required for
the patient with subsequent potential benefit in terms of
adherence. It is important to note however, that such
combination inhalers contain fixed doses of two types of
drug, implying that it is more difficult to alter the dose of
antiinflammatory therapy without altering the dose of long-
acting β2-agonist. This may mean that some patients take
insufficient or excessive amounts of inhaled corticosteroids.
When reviewed at clinic, it might be advantageous for
patients using such combination inhalers to undergo
measurement of a reliable inflammatory biomarker. InTherapeutics and Clinical Risk Management 2005:1(2) 91
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patients with persistent symptoms and evidence of ongoing
inflammation, further antiinflammatory treatment – with
either a higher inhaled corticosteroid dose or leukotriene
receptor antagonist – could be instituted. In asymptomatic
patients and no evidence of ongoing inflammation, the
inhaled corticosteroid dose could be tapered and the patient
reassessed several months later.
It may well be that evaluating asthma control with
inflammatory biomarkers and AHR in “real life” settings
along with conventional parameters will lead to better long-
term outcomes, including effects upon airway remodeling
and minimization of systemic adverse sequelae. This may
in turn reduce the burden of chronic asthma in primary and
secondary care settings alike.
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